As of 21 March 2019, a total of 250,000 people are reported to be affected by the floods in nine districts. An estimated 48 per cent of the affected population is under 18 years of age.
There is limited road access in the Chimanimani, the worst affected district.
An estimated 60,000 children are ...in need of immediate protection services, and 100,000 children are in need of welfare and civil registration services in nine flood affected districts.
Initial estimates indicate that 54 classrooms from 114 schools have been affected by the floods, impacting about 30,000 learners. Over 5,000 households have been reached with critical WASH Hygiene kits in affected districts.
more
Harm Reduction Journal (2016) 13:28
DOI 10.1186/s12954-016-0118-x
The purpose of this study was to document a technical assessment of a sample of these existing shelters on their functionality, accessibility, operation and management, community perspectives in Myanmar; identify gaps, needs and further the linkages with community-based disaster risk reduction (CDBR...R) activities. The study also aims at a wider assessment: looking at broader recovery in terms of shelter and livelihood aspects with clear linkages and strategic direction for future cyclone shelter support activities.
No publication year indicated.
more
J Epidemiol Infect Dis 1(1): 00003.n DOI: 10.15406/jeid.2017.01.00003
Published: September 14, 2017
A Resource Book of Inclusive Practices
The ECA, says over 300,000 Africans could lose their lives due to COVID-19. This, as the pandemic continues to impact on the Continent’s struggling economies whose growth is expected to slow down from 3.2 percent to 1.8 percent in a best-case scenario, pushing close to 27 million people into extr...eme poverty.
more
A review of policy and practice; zero Hunger Phase 1
A Technical Paper. Final Report
Policy Brief | April 2015 | This brief accompanies the data sheet, Addressing Risk Factors for Noncommunicable Diseases Among Young People in Africa: Key to Prevention and Sustainable Development, and its data appendix, which provide all available country-specific data on four key NCD risk factors a...mong young people in Africa since 2004. These publications extend an earlier publication, Noncommunicable Disease Risk Factors Among Young People in Africa: Data Availability and Sources. All are available at www.prb.org/Publications/Datasheets/2015/ncd-risk-youth-africa.aspx.
more
Most of the global burden of sepsis occurs in low- and middle-income countries (LMICs), but the prevalence and etiology of sepsis in LMICs are not well understood. In particular, the lack of laboratory infrastructure in many LMICs has historically precluded an assessment of the pathogens leading to ...sepsis. A recent systematic review found that data describing antimicrobial resistance were absent for 43% of countries in Africa, and only two countries have national antimicrobial resistance plans. In addition, small studies have identified indiscriminate antibiotic use both in and out of hospital settings in sub-Saharan Africa. The absence of microbiological data and lack of antibiotic stewardship complicate sepsis management and almost certainly worsens outcomes, particularly in low-resource systems. The purpose of this study was to examine the prevalence, etiology, and outcomes of sepsis among a cohort of critically ill patients in a referral hospital of Malawi, with a focus on the prevalence of culture-confirmed bacteremia and urinary tract infections.
more
To support its R&D activities on Chagas disease, DNDi launched the Chagas Clinical Research Platform (CCRP). The platform brings together partners, experts, and stakeholders to provide support for evaluation and development of new treatments for Chagas disease. The patient-centred platform aims to f...acilitate clinical research, provide a forum for technical discussions, develop a critical mass of expertise, and strengthen institutional research capacities. In addition, it identifies and reviews priority needs, works towards standardization of methodology to assess drug efficacy and reviews alternatives for using current approved drugs (new schemes, doses, combination) and special scenarios (resistance).
more